Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure

Last updated: October 28, 2021
Sponsor: Shanghai Zhongshan Hospital
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Heart Failure

Chest Pain

Congestive Heart Failure

Treatment

N/A

Clinical Study ID

NCT05111769
SEPSIS-HF
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The investigators intend to conduct clinical studies to determine the efficacy of rhBNP in the treatment of septic related dysfunction and kidney dysfunction

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • sepsis complicated with heart failure（Diagnosed by sepsis 3.0）
  • Heart failure: BNP rises by 600 pg/ml
  • Age>=18 years old

Exclusion

Exclusion Criteria:

  • Hemodynamically unstable
  • Pregnant
  • Disagree with comprehensive and active life support treatment
  • coronary heart disease, myocardial infarction, and cardiac insufficiency
  • chronic renal insufficiency

Study Design

Total Participants: 70
Study Start date:
December 01, 2021
Estimated Completion Date:
December 01, 2023

Study Description

Sepsis is one of the common critical diseases in ICU with high mortality. Septic shock patients are often accompanied by multiple organ dysfunction (MODS), of which more than 50% of patients with varying degrees of myocardial injury.The investigators hope to find a drug with a protective effect on cardiac function and kidney function, so as to treat sepsis more effectively in the treatment of sepsis.

Recombinant human brain natriuretic peptide (rhBNP) was approved by FDA in 2001 for the treatment of acute decompensated heart failure.These effects play a role in the protection of cardiac and kidney function, and have achieved good results in patients with cardiac insufficiency and AKI caused by cardiac surgery.

The investigators are going to carry out related research from the following aspects: 1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.

Connect with a study center

  • Ju Minjie

    Shanghai, Shanghai 200000
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.